Tumor Type

Mexico
United States
(partner)
Breast Cancer - Ductal carcinoma
Project Profile
Funding Organizations
Research Organizations
Research Activities
Publication Policy

1:   ICGC Goals, Structure, Policies and Guidelines Section E.3 - Publication Policy HTML 
2:   Template Letters to Facilitate Communications HTML 
to ensure appropriate dialogue between data users and generators and for authors to contact ICGC members and editors
Clinic & Pathology

Mexico: FUCAM
Instituto Nacional de Medicina Genomica
United States: Broad Institute

The Broad Institute, INMEGEN, and FUCAM are performing pathology review, clinical data collection and annotation of available breast cancer specimens (both frozen and formalin fixed paraffin embedded tissues).

Sequencing & Analysis

United States: Broad Institute
Dana-Farber Cancer Institute

Breast cancer is one of the most common cancer diagnoses worldwide and is a leading cause of cancer related death in women, particularly in Mexico, where the age of onset is reported to be significantly earlier than in the United States and Europe. The identification of key genes leading to breast cancer pathogenesis will aid the development of more rationally designed and effective therapy.

The breast cancer samples being studied in the Mexico/US ICGC Breast Cancer project are made up of two sub-collections: 78 patients from Mexico supplied by our collaborator, by Dr. Alfredo Hidalgo, at INMEGEN and, to facilitate comparison to the Mexican population, 60 patients of Asian descent. We have performed whole-exome sequencing on 116 of these samples, likely representing the world’s largest breast cancer genome sequencing effort to date. In addition, whole-genome sequencing was performed on 24 patients.

Complementary Studies

Data Storage, Analysis & Management

United States: National Center for Biotechnology Information

Sequencing, SNP, Copy Number, and Variant call information will be stored at NCBI and dbGAP for data sharing and distribution purposes.

The dbGAP accession number for this sequencing project is phs000369.v1.p1.

Project Summary

Breast cancer is one of the most common cancer diagnoses worldwide and is a leading cause of cancer related death in women, particularly in Mexico, where the age of onset is reported to be significantly earlier than in the United States and Europe. The identification of key genes leading to breast cancer pathogenesis will aid the development of more rationally designed and effective therapy.

The breast cancer samples being studied in the Mexico/US ICGC Breast Cancer project are made up of two sub-collections: 78 patients from Mexico supplied by our collaborator, Dr. Alfredo Hidalgo, at IMEGEN and, to facilitate comparison to the Mexican population, 60 patients of Asian descent. We have performed whole-exome sequencing on 116 of these samples, likely representing the world’s largest breast cancer genome sequencing effort to date. In addition, whole-genome sequencing has been performed on 24 patients.

The project is now planning to invest resources over the next several years into the functional validation of findings arising from the initial sequencing and analysis of these breast cancer specimens.

Slim Initiative for Genomic Medicine:

This work is conducted as part of the Slim Initiative for Genomic Medicine (SIGMA), a joint U.S.-Mexico project funded by the Carlos Slim Health Institute. The SIGMA cancer project aims to understand the genomic basis of cancer in worldwide populations by extensive analysis of at least 560 cancer pairs across at least 7 different cancers to obtain an initial molecular taxonomy of the mutations present in these cancer types.

Principal Investigators

Todd Golub
Matthew Meyerson
Alfredo Hidalgo-Miranda
Jorge Melendez

Lead Jurisdiction